Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 7.37TCr 6.41TCr 5.97TCr 5.48TCr 10TCr 7,03800Cr 11TCr 70TCr 28TCr 3,50400Cr 28TCr 27TCr 11,74900Cr P/E 2026 *
17.5x
P/E 2027 * 14.7x
Enterprise Value 6.69TCr 5.81TCr 5.41TCr 4.97TCr 9.38TCr 6,38200Cr 9.52TCr 64TCr 25TCr 3,17700Cr 25TCr 25TCr 10,65400Cr EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.46x
Free-Float
72.32%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
1 day+3.29%
1 week+16.25%
Current month+22.31%
1 month+22.08%
3 months+8.73%
6 months+1.01%
Current year-1.20%
1 week 659.53
Extreme 659.53
764.75
1 month 625.7
Extreme 625.7
764.75
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-200 0.0002%
19/02/26 Fiscal year

Director

4,914 0.0048%
09/02/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+3.29%+16.25%+39.81%+2.79% 7.51TCr
+2.72%-8.27%+20.23%+179.60% 4.76TCr
-2.75%+48.50%+48.50%+48.50% 4.95TCr
-3.81%+6.32%-54.61%-53.87% 4.29TCr
-2.40%+0.38%+58.55%-24.89% 3.07TCr
-2.82%+1.57%+59.59%+87.57% 2.49TCr
-5.35%+1.39%+85.45%-53.41% 2.3TCr
-1.59%-4.78%-11.93%+136.89% 1.96TCr
-0.42%+2.66%+68.31%+128.45% 1.72TCr
-2.50%-4.68%+69.43%+128.76% 1.61TCr
Average -1.56%+2.45%+38.33%+58.04% 3.47TCr
Weighted average by Cap. -0.77%+3.22%+32.64%+46.14%

Financials

2026 *2027 *
Net sales 1.69TCr 1.47TCr 1.37TCr 1.25TCr 2.37TCr 1,61100Cr 2.4TCr 16TCr 6.32TCr 80TCr 6.34TCr 6.2TCr 2,68900Cr 1.82TCr 1.59TCr 1.48TCr 1.36TCr 2.56TCr 1,74200Cr 2.6TCr 17TCr 6.83TCr 87TCr 6.85TCr 6.7TCr 2,90700Cr
Net income 460.64Cr 400.43Cr 372.71Cr 342.2Cr 646.21Cr 44TCr 656.22Cr 4.39TCr 1.72TCr 22TCr 1.73TCr 1.69TCr 73TCr 535.26Cr 465.3Cr 433.09Cr 397.63Cr 750.9Cr 51TCr 762.53Cr 5.11TCr 2TCr 25TCr 2.01TCr 1.97TCr 85TCr
Net Debt -686.84Cr -597.07Cr -555.74Cr -510.24Cr -963.54Cr -66TCr -978.47Cr -6.55TCr -2.57TCr -33TCr -2.58TCr -2.52TCr -1,09500Cr -1.06TCr -917.44Cr -853.94Cr -784.02Cr -1.48TCr -1,00700Cr -1.5TCr -10TCr -3.95TCr -50TCr -3.96TCr -3.88TCr -1,68200Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
01/26/01 $762.63 +3.29% 11,57,894
30/26/30 $738.34 +6.17% 14,60,963
29/26/29 $695.42 +0.03% 10,22,421
28/26/28 $695.18 +4.20% 9,00,408
27/26/27 $667.17 +1.70% 6,50,984
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
738.34USD
Average target price
829.10USD
Spread / Average Target
+12.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock